[Gene therapy in Parkinson disease: a promising future treatment?].
Identifieur interne : 000951 ( PubMed/Corpus ); précédent : 000950; suivant : 000952[Gene therapy in Parkinson disease: a promising future treatment?].
Auteurs : Claire Golé ; Romain Reboul ; Pascale PisanoSource :
- Therapie [ 0040-5957 ]
English descriptors
- KwdEn :
- MESH :
- chemical , genetics : Aromatic-L-Amino-Acid Decarboxylases, Glutamate Decarboxylase, Tyrosine 3-Monooxygenase.
- methods : Genetic Therapy.
- therapy : Parkinson Disease.
- trends : Genetic Therapy.
- Clinical Trials as Topic, Genetic Vectors, Humans.
Abstract
Parkinson disease is a neurodegenerative pathology with high incidence. Current treatments ease the symptoms but don't stop the development of the disease and aren't without any major side effects. Although this pathology is not specifically caused by genetic abnormalities, the involvement of numerous proteins in the pathophysiological process enables us to give an interest to gene therapy. This hypothesis has been upheld by positive results on animals and by five phase I trials on humans but may be attenuated by the first phase II trial recently published showing modest efficiency and multiple side effects. However, these preliminary results will need to be reinforced by more important trials in order to be sure of the safety and get efficacy data, which will allow us to give an opinion upon this new way of treatment.
DOI: 10.2515/therapie/2011062
PubMed: 22031685
Links to Exploration step
pubmed:22031685Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Gene therapy in Parkinson disease: a promising future treatment?].</title><author><name sortKey="Gole, Claire" sort="Gole, Claire" uniqKey="Gole C" first="Claire" last="Golé">Claire Golé</name><affiliation><nlm:affiliation>Hopital de la Timone, Marseille, France. claire.gole@ap-hm.fr</nlm:affiliation></affiliation></author><author><name sortKey="Reboul, Romain" sort="Reboul, Romain" uniqKey="Reboul R" first="Romain" last="Reboul">Romain Reboul</name></author><author><name sortKey="Pisano, Pascale" sort="Pisano, Pascale" uniqKey="Pisano P" first="Pascale" last="Pisano">Pascale Pisano</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2011 Sep-Oct</MedlineDate></PubDate></date><idno type="RBID">pubmed:22031685</idno><idno type="pmid">22031685</idno><idno type="doi">10.2515/therapie/2011062</idno><idno type="wicri:Area/PubMed/Corpus">000951</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000951</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Gene therapy in Parkinson disease: a promising future treatment?].</title><author><name sortKey="Gole, Claire" sort="Gole, Claire" uniqKey="Gole C" first="Claire" last="Golé">Claire Golé</name><affiliation><nlm:affiliation>Hopital de la Timone, Marseille, France. claire.gole@ap-hm.fr</nlm:affiliation></affiliation></author><author><name sortKey="Reboul, Romain" sort="Reboul, Romain" uniqKey="Reboul R" first="Romain" last="Reboul">Romain Reboul</name></author><author><name sortKey="Pisano, Pascale" sort="Pisano, Pascale" uniqKey="Pisano P" first="Pascale" last="Pisano">Pascale Pisano</name></author></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aromatic-L-Amino-Acid Decarboxylases (genetics)</term><term>Clinical Trials as Topic</term><term>Genetic Therapy (methods)</term><term>Genetic Therapy (trends)</term><term>Genetic Vectors</term><term>Glutamate Decarboxylase (genetics)</term><term>Humans</term><term>Parkinson Disease (therapy)</term><term>Tyrosine 3-Monooxygenase (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Aromatic-L-Amino-Acid Decarboxylases</term><term>Glutamate Decarboxylase</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Genetic Therapy</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Genetic Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Genetic Vectors</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson disease is a neurodegenerative pathology with high incidence. Current treatments ease the symptoms but don't stop the development of the disease and aren't without any major side effects. Although this pathology is not specifically caused by genetic abnormalities, the involvement of numerous proteins in the pathophysiological process enables us to give an interest to gene therapy. This hypothesis has been upheld by positive results on animals and by five phase I trials on humans but may be attenuated by the first phase II trial recently published showing modest efficiency and multiple side effects. However, these preliminary results will need to be reinforced by more important trials in order to be sure of the safety and get efficacy data, which will allow us to give an opinion upon this new way of treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22031685</PMID><DateCreated><Year>2011</Year><Month>10</Month><Day>27</Day></DateCreated><DateCompleted><Year>2012</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2011</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>5</Issue><PubDate><MedlineDate>2011 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Gene therapy in Parkinson disease: a promising future treatment?].</ArticleTitle><Pagination><MedlinePgn>413-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2515/therapie/2011062</ELocationID><Abstract><AbstractText>Parkinson disease is a neurodegenerative pathology with high incidence. Current treatments ease the symptoms but don't stop the development of the disease and aren't without any major side effects. Although this pathology is not specifically caused by genetic abnormalities, the involvement of numerous proteins in the pathophysiological process enables us to give an interest to gene therapy. This hypothesis has been upheld by positive results on animals and by five phase I trials on humans but may be attenuated by the first phase II trial recently published showing modest efficiency and multiple side effects. However, these preliminary results will need to be reinforced by more important trials in order to be sure of the safety and get efficacy data, which will allow us to give an opinion upon this new way of treatment.</AbstractText><CopyrightInformation>© 2011 Société Française de Pharmacologie et de Thérapeutique.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Golé</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hopital de la Timone, Marseille, France. claire.gole@ap-hm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reboul</LastName><ForeName>Romain</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pisano</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>La thérapie génique dans la maladie de Parkinson : un traitement d'avenir ?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber><NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.28</RegistryNumber><NameOfSubstance UI="D001142">Aromatic-L-Amino-Acid Decarboxylases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001142" MajorTopicYN="N">Aromatic-L-Amino-Acid Decarboxylases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005968" MajorTopicYN="N">Glutamate Decarboxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22031685</ArticleId><ArticleId IdType="doi">10.2515/therapie/2011062</ArticleId><ArticleId IdType="pii">th111994</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000951 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000951 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22031685
|texte= [Gene therapy in Parkinson disease: a promising future treatment?].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22031685" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |